H.C. Wainwright cuts Rapport Therapeutics target price to $63 from $66
RAPP•H.C. Wainwright cut its target price for Rapport Therapeutics to $63 from $66.
Related News
V.F. Corporation: Barclays raises target price to $28 from $24
VFC•
Toyota names Mark Templin North America CEO effective Jan. 1, 2027
TM•
Cigna raises 2026 adjusted EPS guidance to at least $30.60
CI•
Targa Resources Q3 revenue jumps 35%, beats estimates
TRGP•
Viridian Therapeutics target price raised to $40 from $22 by H.C. Wainwright
VRDN•